Literature DB >> 7204576

Cyclosporin a. Inhibition of experimental autoimmune uveitis in Lewis rats.

R B Nussenblatt, M M Rodrigues, W B Wacker, S J Cevario, M C Salinas-Carmona, I Gery.   

Abstract

Cyclosporin A (CS-A), a selective inhibitor of T lymphocytes, is reported here to prevent S antigen (S-Ag) induced uveitis in Lewis rats. The S-Ag, found in all mammalian retinas, is uveitogenic under experimental conditions and patients with certain uveitic entities demonstrate cell mediated responses to this antigen. Daily treatment with CS-A (10 mg/kg) begun on the same day as S-Ag immunization totally inhibited the development of the uveitis in this experimental autoimmune model. Moreover a greater CS-A dose (40 mg/kg) efficiently prevented the disease process when therapy was started 7 d after S-Ag immunization. Anti-S-Ag antibody titers were observed to be similar in rats either protected or not protected with CS-A. Our data support strongly the need for T cell participation in this disease model. Since ocular inflammatory disease is an important cause of visual impairment, the data further suggest that CS-A may be useful in the treatment of patients with intractable uveitis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7204576      PMCID: PMC370685          DOI: 10.1172/jci110138

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  Experimental allergic uveitis. Isolation, characterization, and localization of a soluble uveitopathogenic antigen from bovine retina.

Authors:  W B Wacker; L A Donoso; C M Kalsow; J A Yankeelov; D T Organisciak
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

3.  Experimental autoimmune uveitis: cellular immune responsiveness.

Authors:  R B Nussenblatt; I Gery; W B Wacker
Journal:  Invest Ophthalmol Vis Sci       Date:  1980-06       Impact factor: 4.799

4.  Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.

Authors:  A D Hess; P J Tutschka
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

5.  Enzyme-linked immunoassay (ELISA) for connective tissue components.

Authors:  S I Rennard; R Berg; G R Martin; J M Foidart; P G Robey
Journal:  Anal Biochem       Date:  1980-05-01       Impact factor: 3.365

6.  Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

Authors:  R Y Calne; K Rolles; D J White; S Thiru; D B Evans; P McMaster; D C Dunn; G N Craddock; R G Henderson; S Aziz; P Lewis
Journal:  Lancet       Date:  1979-11-17       Impact factor: 79.321

7.  Suppression of in vitro lymphocyte reactivity by cyclosporin A: existence of a population of drug-resistant cytotoxic lymphocytes.

Authors:  T Horsburgh; P Wood; L Brent
Journal:  Nature       Date:  1980-08-07       Impact factor: 49.962

8.  Cellular immune responsiveness of uveitis patients to retinal S-antigen.

Authors:  R B Nussenblatt; I Gery; E J Ballintine; W B Wacker
Journal:  Am J Ophthalmol       Date:  1980-02       Impact factor: 5.258

9.  Cyclosporin A to prevent graft-versus-host disease in man after allogeneic bone-marrow transplantation.

Authors:  R L Powles; H M Clink; D Spence; G Morgenstern; J G Watson; P J Selby; M Woods; A Barrett; B Jameson; J Sloane; S D Lawler; H E Kay; D Lawson; T J McElwain; P Alexander
Journal:  Lancet       Date:  1980-02-16       Impact factor: 79.321

10.  Effect of cyclosporin A on the survival of corneal grafts in rabbits.

Authors:  W F Shepherd; D J Coster; T C Fook; N S Rice; B R Jones
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

View more
  37 in total

Review 1.  Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium.

Authors:  A D Dick; J D Isaacs
Journal:  Br J Ophthalmol       Date:  1999-11       Impact factor: 4.638

2.  Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific.

Authors:  B Laliotou; J Liversidge; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  1997-01       Impact factor: 4.638

Review 3.  Endogenous posterior uveitis.

Authors:  J V Forrester
Journal:  Br J Ophthalmol       Date:  1990-10       Impact factor: 4.638

Review 4.  Immunoregulation of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-01       Impact factor: 2.031

Review 5.  Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A.

Authors:  A D Dick; M Azim; J V Forrester
Journal:  Br J Ophthalmol       Date:  1997-12       Impact factor: 4.638

6.  Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats.

Authors:  S M Robertson; L S Lang
Journal:  Agents Actions       Date:  1994-10

7.  Prevention of diabetes mellitus in the BB/W rat with Cyclosporin-A.

Authors:  A A Like; V Dirodi; S Thomas; D L Guberski; A A Rossini
Journal:  Am J Pathol       Date:  1984-10       Impact factor: 4.307

8.  Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.

Authors:  Pinar Cakar Ozdal; Serap Ortaç; Ibrahim Taskintuna; Esin Firat
Journal:  Doc Ophthalmol       Date:  2002-11       Impact factor: 2.379

9.  Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats.

Authors:  M Neidhart
Journal:  Experientia       Date:  1996-09-15

10.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.